Novacyt, the Anglo-French biotechnology group, announced on Thursday that it anticipates a decline in revenue for the first half of the year. The decrease is attributed to the high comparative figure from the previous year, primarily due to Covid-19-related instrumentation sales.

The company forecasts revenue of £3.3 million ($4.3 million) for the first half, a notable decrease from the £16.5 million reported in the same period last year. Revenue related to Covid-19 amounted to £500,000 in the first half, compared to £13 million in the prior year.

Despite the decline in Covid-19 revenue, Novacyt noted that its non-Covid-19 revenue continued to show growth. In the second quarter, it increased by 3% compared to the first quarter and by 10% compared to the fourth quarter of 2022.

Operational expenditure for the first half is expected to be £7.1 million, indicating a reduction of approximately 13% from the second half of 2022. This reduction reflects the restructuring plans that were implemented in the previous fourth quarter.

Recognizing the significance of the U.K. market for its clinical diagnostics products, Novacyt will prioritize U.K. Conformity Assessed (UKCA) marking for a selection of its new multiplex tests.

The company remains steadfast in its commitment to expand its product portfolio, drive international Research Use Only (RUO) sales, and seek strategic business development opportunities. Novacyt aims to build on the strength of its core business and deliver long-term sustainable growth.

Stock Market Update

Vivendi Announces Agreement to Sell Gala Magazine

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Challenges Faced by Arm Holdings PLC's Shares
News

Challenges Faced by Arm Holdings PLC's Shares

Shares of Arm Holdings PLC have faced challenges and decline in the stock market. Analysts remain cautious about its fut...

Netflix Shares Experience Drop
News

Netflix Shares Experience Drop

Netflix Inc. encountered a 1.60% decline in share value, breaking a two-day winning streak and falling just short of the...

Nikola Corp. Rejects 'Dissident' Nominees to Board of Directors
News

Nikola Corp. Rejects 'Dissident' Nominees to Board of Directors

Nikola Corp. rejects board nominees proposed by Trevor Milton, citing lack of experience and expertise. Stock continues...

Stadler Rail Reports Strong Performance in First Half
News

Stadler Rail Reports Strong Performance in First Half

Shares of Stadler Rail surge after strong performance with increased free cash flow and solid order intake.